journal article·2025-05Open access

Polymeric Anti‐Antibiotic Microparticles to Prevent Antibiotic Resistance Evolution (Small 21/2025)

Roya Koshani, Shang‐Lin Yeh, Zeming He, Naveen Narasimhalu, Landon G. vom Steeg, Derek G. Sim, Robert J. Woods, Andrew F. Read, Amir Sheikhi

Small· Volume 21· Issue 21

Abstract

Antibiotic Resistance In article number 2407549, Amir Sheikhi and co-workers report sevelamer (SEV), a Food and Drug Administration (FDA)-approved polymeric microparticle, as an adjuvant therapy to combat antimicrobial resistance. SEV captures off-target vancomycin and daptomycin in the gastrointestinal tract, preventing resistance enrichment in Enterococcus faecium. SEV therapy protects the last-resort antibiotics, which may address the global antimicrobial resistance crisis. Image created with BioRender.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Innovative Microfluidic and Catalytic Techniques Innovation · Enzyme Catalysis and Immobilization · Medical and Biological Ozone Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering The Pennsylvania State University University Park PA 16802 USA

Department of Biology and Entomology The Pennsylvania State University University Park PA 16802 USA

Department of Microbiology and Immunology Geisel School of Medicine at Dartmouth Lebanon NH 03756 USA

Huck Institutes of the Life Sciences The Pennsylvania State University University Park PA 16802 USA

Department of Internal Medicine University of Michigan Ann Arbor MI 48109 USA

Department of Biomedical Engineering The Pennsylvania State University University Park PA 16802 USA

Department of Chemistry The Pennsylvania State University University Park PA 16802 USA

Department of Neurosurgery College of Medicine The Pennsylvania State University Hershey PA 17033 USA

References

Reference metadata was not supplied for this record.